Premium Company Profile: Cardiome Pharma Corp.

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Report
Pages	43
ISBN Number	not applicable
Product Code	DAT08639

Price

£265.00
approximately: $495 | €336

PDF

PRINT £315 ($589 | €400)

Order above formats by FAX

Summary

Cardiome Pharma is a product based drug development company for the treatment of cardiovascular diseases. The company has two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a pre-clinical program directed at improving cardiovascular function and Artesian projects in the pre-clinical stage of development.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Cardiome is experienced in discovering and developing therapeutics for cardiovascular diseases. The company entered into an agreement with Astellas Therapeutics, wherein Cardiome granted rights to market its lead candidate Vernakalant (intravenous) in North America, if and when it is approved by the FDA.

The company derives its revenues from contract, licensing and collaboration. During 2002-2006, the company's total revenues growth was at a CAGR of 85%. The only revenues are from licensing and collaboration.

During the period 2006-2010, Cardiome's total revenues are forecasted to grow from $18 million to $110 million. Vernakalent royalties is expected to be the main growth driver of revenues for Cardiome, generating sales growth of +$81 million during the period 2006-2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Table Of Contents
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview And Key Facts
- Business Description
- History
- Locations And Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors And Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- Swot Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- Key Employee Biographies
- Financial And Operational Overview
- Financial And Operational Overview
Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table Of Figures
- Figure 1: Cardiome Pharma - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Cardiome Pharma - Key Strategic Revenues, 2006-2010 ($ Mn)
Table Of Tables
- Table 1: Cardiome Pharma - Key Facts
- Table 2: Cardiome Pharma - Other Locations And Subsidiaries
- Table 3: Cardiome Pharma - Year-End Share Price And Market Capitalization, 2002-2006 ($)
- Table 4: Cardiome Pharma - Key Events Impacting Share Price Performance
- Table 5: Cardiome Pharma - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Cardiome Pharma - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
- Table 7: Cardiome Pharma - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Cardiome Pharma - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Cardiome Pharma - In-House Pipeline Products
- Table 10: Cardiome Pharma - Collaboration Products
- Table 11: Cardiome Pharma - Forecast Sales, 2006-2010 ($ Mn)
- Table 12: Cardiome Pharma - Key Competitors
- Table 13: Cardiome Pharma - Key Suppliers
- Table 14: Cardiome Pharma - Key Clients
- Table 15: Cardiome Pharma - Key Shareholders
- Table 16: Cardiome Pharma - Swot Analysis Summary
- Table 17: Cardiome Pharma - Value Chain Analysis
- Table 18: Cardiome Pharma - Scorecard
- Table 19: Cardiome Pharma - Key Employees
- Table 20: Cardiome Pharma - Financial And Operational Overview